Search research articles
Contact Us
Filters
Showing results (241-250 of 294) with videos related to
Page
of 30
Sort By:
Blood
|
February 17, 2017
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
Tabea Erdmann, Pavel Klener, James T Lynch, et al.
Science (New York, N.Y.)
|
March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Georg Lenz, R Eric Davis, Vu N Ngo, et al.
Histopathology
|
February 28, 2023
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
Yasodha Natkunam, Daphne de Jong, Pedro Farinha, et al.
Journal of Hematology & Oncology
|
February 21, 2026
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party
Evgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Hemasphere
|
August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party
Philipp Berning, Maud Ngoya, Won Seog Kim, et al.
Leukemia
|
August 16, 2024
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration
Fabian Frontzek, Loïc Renaud, Ulrich Dührsen, et al.
Hemasphere
|
September 25, 2025
Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across Europe
Florence Broussais, Elise Pennings, Natacha Bolanos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2017
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Lancet (London, England)
|
May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
Georg Lenz, Marek Trněný, John M Burke, et al.
Blood
|
November 20, 2016
B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Beiying Dai, Michael Grau, Mélanie Juilland, et al.
Page
of 30
Search research articles
Search
Showing results (241-250 of 294) with videos related to
Sort By:
Page
of 30
Blood
|
February 17, 2017
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
Tabea Erdmann, Pavel Klener, James T Lynch, et al.
Science (New York, N.Y.)
|
March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Georg Lenz, R Eric Davis, Vu N Ngo, et al.
Histopathology
|
February 28, 2023
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
Yasodha Natkunam, Daphne de Jong, Pedro Farinha, et al.
Journal of Hematology & Oncology
|
February 21, 2026
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party
Evgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Hemasphere
|
August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party
Philipp Berning, Maud Ngoya, Won Seog Kim, et al.
Leukemia
|
August 16, 2024
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration
Fabian Frontzek, Loïc Renaud, Ulrich Dührsen, et al.
Hemasphere
|
September 25, 2025
Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across Europe
Florence Broussais, Elise Pennings, Natacha Bolanos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2017
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Lancet (London, England)
|
May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
Georg Lenz, Marek Trněný, John M Burke, et al.
Blood
|
November 20, 2016
B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Beiying Dai, Michael Grau, Mélanie Juilland, et al.
Page
of 30